Hepatitis C virus drug resistance–associated substitutions: State of the art summary

Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot‐Matias, Veronica Miller – 10 June 2015 – Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are potent and highly efficacious, the full clinical impact of HCV drug resistance, its implications for retreatment, and the potential role of baseline resistance testing remain critical research and clinical questions.

Propensity score‐based survival benefit of simultaneous liver‐kidney transplant over liver transplant alone for recipients with pretransplant renal dysfunction

Pratima Sharma, Xu Shu, Douglas E. Schaubel, Randall S. Sung, John C. Magee – 9 June 2015 – The survival benefit of simultaneous liver‐kidney transplantation (SLKT) over liver transplantation alone (LTA) is unclear from the current literature. Additionally, the role of donor kidney quality, measured by the kidney donor risk index (KDRI), in survival benefit of SLKT is not studied.

Reply

Patricia Martinez‐Ortega, Fernando Rotellar, Pablo Marti‐Cruchaga, Gabriel Zozaya, Carlos Sanchez‐Justicia, Fernando Pardo – 9 June 2015

Liver transplantation for critically Ill patients with secondary sclerosing cholangitis: Outcome and complications

Torsten Voigtländer, Elmar Jaeckel, Frank Lehner, Michael P. Manns, Tim O. Lankisch – 9 June 2015 – Secondary sclerosing cholangitis in critically ill patients (SSC‐CIP) is a destructive cholangiopathy with a poor prognosis. Liver transplantation (LT) is an established therapeutic option in end‐stage liver disease but is insufficiently evaluated in patients with SSC‐CIP. Our aim was the retrospective analysis of the outcome and complications of patients with SSC‐CIP undergoing LT between 2002 and 2012.

Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma

Yinying Lu, Wanping Xu, Junfang Ji, Dechun Feng, Carole Sourbier, Youfeng Yang, Jianhui Qu, Zhen Zeng, Chunping Wang, Xiujuan Chang, Yan Chen, Alok Mishra, Max Xu, Min‐Jung Lee, Sunmin Lee, Jane Trepel, W. Marston Linehan, Xinwei Wang, Yongping Yang, Len Neckers – 8 June 2015 – The cell fate determinant Numb is aberrantly expressed in cancer. Numb is alternatively spliced, with one isoform containing a long proline‐rich region (PRRL) compared to the other with a short PRR (PRRS). Recently, PRRL was reported to enhance proliferation of breast and lung cancer cells.

Subscribe to